
    
      The purpose of this study is to investigate the effect of 3 different regimens of
      subcutaneous (SC) administered hCRF (1.0 mg every [Q] 8 hours [h], 1.5 mg Q12h, and 1.0 mg
      Q12h) on the reduction of PBE in patients with primary malignant or metastatic brain tumors
      as defined by MRI indexes.
    
  